GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearmind Medicine Inc (NAS:CMND) » Definitions » Beta

Clearmind Medicine (Clearmind Medicine) Beta : N/A (As of May. 24, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Clearmind Medicine Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-05-24), Clearmind Medicine's Beta is Not available.


Clearmind Medicine Beta Historical Data

The historical data trend for Clearmind Medicine's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearmind Medicine Beta Chart

Clearmind Medicine Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Beta
Get a 7-Day Free Trial - - - - -

Clearmind Medicine Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Clearmind Medicine's Beta

For the Biotechnology subindustry, Clearmind Medicine's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clearmind Medicine's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearmind Medicine's Beta distribution charts can be found below:

* The bar in red indicates where Clearmind Medicine's Beta falls into.



Clearmind Medicine Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Clearmind Medicine  (NAS:CMND) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Clearmind Medicine Beta Related Terms

Thank you for viewing the detailed overview of Clearmind Medicine's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Clearmind Medicine (Clearmind Medicine) Business Description

Traded in Other Exchanges
Address
101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H 1A5
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Clearmind Medicine (Clearmind Medicine) Headlines

From GuruFocus